These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22416019)

  • 1. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.
    Ananthakrishnan AN; Korzenik JR; Hur C
    Inflamm Bowel Dis; 2013 Jan; 19(1):37-44. PubMed ID: 22416019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.
    Ananthakrishnan AN; Hur C; Juillerat P; Korzenik JR
    Am J Gastroenterol; 2011 Nov; 106(11):2009-17. PubMed ID: 21788991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
    Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
    J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
    Tang DH; Armstrong EP; Lee JK
    Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.
    Doherty GA; Miksad RA; Cheifetz AS; Moss AC
    Inflamm Bowel Dis; 2012 Sep; 18(9):1608-16. PubMed ID: 21905173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2009 Sep; 15(9):1295-301. PubMed ID: 19340881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
    Punekar YS; Sunderland T; Hawkins N; Lindsay J
    Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
    Alizadeh ER; Dervieux T; Vermeire S; Dubinsky M; D'Haens G; Laharie D; Shim A; Vaughn BP
    Pharmacotherapy; 2024 Apr; 44(4):331-342. PubMed ID: 38576238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.
    Kaplan GG; Hur C; Korzenik J; Sands BE
    Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1509-20. PubMed ID: 17931345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.
    Velayos FS; Kahn JG; Sandborn WJ; Feagan BG
    Clin Gastroenterol Hepatol; 2013 Jun; 11(6):654-66. PubMed ID: 23357488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
    Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
    J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease.
    Bolin K; Hertervig E; Louis E
    J Crohns Colitis; 2019 Sep; 13(10):1323-1333. PubMed ID: 30893421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
    Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
    Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of infliximab in Crohn's disease.
    Smart C; Selinger CP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.
    Bodger K; Kikuchi T; Hughes D
    Aliment Pharmacol Ther; 2009 Aug; 30(3):265-74. PubMed ID: 19438428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost-effectiveness of tumor necrosis factor in Crohn's disease].
    Rudakova AV
    Eksp Klin Gastroenterol; 2012; (5):83-6. PubMed ID: 23402177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China.
    Chen H; Shi J; Pan Y; Zhang Z; Fang H; Chen Y; Chen W; Cao Q
    Adv Ther; 2020 Jan; 37(1):431-449. PubMed ID: 31797196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.